3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Brain Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Pain, Postoperative
2
Pain
2
Ovarian Neoplasms
2
Neoplasms
2
Warts
1
Stroke
1
Sepsis
1
Schwannomatosis
1
Prostatic Neoplasms
1
Pleural Effusion
1
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Pancreatic Cyst
1
Neuroinflammatory Diseases
1
Neurilemmoma
1
Multiple Myeloma
1
Metastatic Non-Squamous Non-Small Cell Lung Cancer
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hypoxia
1
Hyperthermia
1
Hemorrhage
1
Glycopyrrolate
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Erectile Dysfunction
1
Colorectal Neoplasms
1
Interventions
Paclitaxel
22
Bevacizumab
20
Carboplatin
19
liposomal doxorubicin
14
Specimen Handling
14
Magnetic Resonance Spectroscopy
13
olaparib
12
Topotecan
9
Gemcitabine
9
Biopsy
8
pembrolizumab
7
Taxes
6
Immunoglobulin G
6
Disulfides
6
niraparib
4
mirvetuximab soravtansine
4
cediranib
4
Doxorubicin
4
oregovomab
3
Nivolumab
3
Cyclophosphamide
3
sarilumab
2
rucaparib
2
cemiplimab
2
berzosertib
2
adavosertib
2
Oxaliplatin
2
Docetaxel
2
Cisplatin
2
Biosimilar Pharmaceuticals
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Fallopian Tube Neoplasms
×
Saline Solution
×
90 days
×
Clear all
NCT03740165
2026-05-04
KEYLYNK-001
Merck Sharp & Dohme LLC
Phase 3
Completed
1,367 enrolled
29 charts